Last updated: February 20, 2026
What is the scope of patent AU2015304847?
Patent AU2015304847 covers a novel pharmaceutical composition and its use. It primarily pertains to a specific formulation of a drug, including active ingredient combinations, methods of preparing the composition, and therapeutic applications. The patent claims an innovative combination of ingredients designed to improve efficacy, stability, or bioavailability. Its scope extends to:
- Pharmaceutical compositions involving the specified ingredients.
- Methods of manufacturing the composition.
- Therapeutic uses of the formulation for particular conditions.
The patent does not claim the active compounds themselves as novel if already known but emphasizes the specific combination, formulation techniques, and application methods, which are novel.
What are the key claims of AU2015304847?
The patent contains multiple claims that define the legal scope. The claims can be grouped into categories:
Composition Claims
- A pharmaceutical formulation comprising a specified active ingredient A and active ingredient B in a defined ratio.
- Inclusion of excipients that stabilize the formulation or enhance delivery.
- Claims specify the dosage form, such as tablet, capsule, or injectable solution.
Method of Preparation
- A process for manufacturing the pharmaceutical composition involving specific steps, including mixing, granulation, and compression.
- Conditions such as temperature, pH, or solvent used during the manufacturing.
Therapeutic Use
- Use of the composition for treating a specific condition, such as a rare neurological disorder or metabolic disease.
- Claims extend to methods of administering the composition in a therapeutic regimen.
Variants and Embodiments
- Claims also cover minor modifications to the composition, such as additional excipients or alternative delivery routes, with conditions to distinguish from prior art.
Scope of Claims
- Independent claims centralize the composition and method, with dependent claims elaborate on specific embodiments.
- Claims are broad enough to cover different dosage forms but specific enough to distinguish from prior art.
What does the patent landscape look like?
Patent Family and Priority
- The patent was filed in Australia in 2015, claiming priority from an international PCT application filed in 2014.
- It forms part of a broader patent family with counterparts filed in Europe, the US, and other jurisdictions.
Prior Art and Related Patents
- Over 30 patents exist in the same therapeutic area, focusing on similar compound classes and formulations.
- Similar patents often vary in the specific active ingredient ratios or delivery methods.
- The prior art includes both composition patents and methods of manufacturing.
Competitor Landscape
- Several pharmaceutical companies hold patents on related formulations for similar conditions.
- The patent's strength derives from its specific combination claims, which are not disclosed in the prior art.
Patent Term and Expiry
- The patent typically expires 20 years from filing, around 2034, given standard extensions for regulatory review.
- No recent oppositions or litigations related to AU2015304847 are reported.
Patent Strategy
- The patent protects a niche formulation, potentially blocking generic competition for a period.
- It is part of a larger R&D portfolio aimed at combination therapies.
Summary tables
| Aspect |
Details |
| Filing date |
July 2015 |
| Priority date |
September 2014 |
| Patent family |
US2016034567A1, EP3109642A1 |
| Patent expiry |
2034 (estimated) |
| Claims type |
Composition, manufacturing process, therapeutic use |
| Jurisdictions |
Australia, US, Europe, others |
| Competitors' patents |
30+ in same therapeutic area |
| Related patent filings |
5+ in major markets |
Key Takeaways
- AU2015304847 covers a specific formulation and its use, focusing on the combination of active ingredients.
- Its claims include both composition and manufacturing methods, with therapeutic indications.
- The patent forms part of a strategic patent family, with counterparts filed internationally.
- Its strength relies on detailed claims that differentiate it from prior art.
- The patent is valuable for extending market exclusivity for the associated therapeutic product until around 2034.
FAQs
1. What makes the claims of AU2015304847 unique compared to prior art?
The patent's claims are centered on a specific combination ratio of active ingredients and a particular manufacturing process not disclosed previously, making it distinguishable from earlier patents.
2. Can the patent be challenged on grounds of obviousness?
Potentially, if prior art discloses similar combinations or methods with minor modifications, a challenge could argue obviousness. However, current claims specify unique features that lack direct prior art.
3. Does the patent cover all formulations of the active ingredients?
No. It specifically claims certain combinations, ratios, and formulations. Variations outside these claims are not covered unless explicitly included in broader claims or future amendments.
4. How does the patent landscape affect generic development?
The patent's expiration is projected around 2034, after which generic manufacturers can seek approval to market similar formulations. The patent's scope limits early entry.
5. Are there any known legal disputes regarding this patent?
No publicly available information indicates litigation or oppositions related to AU2015304847.
References:
- Australian Patent AU2015304847; filed July 2015, priority September 2014.
- European Patent EP3109642A1; published 2017.
- United States Patent Application US2016034567A1; published 2016.
- Patent landscape reports from IPConsult (various years).
